Precision Oncology, Precision Immunooncology, Phase I, Biomarker discovery
학력
2005.02 성균관대학교 대학원 내과학 박사
2002.06 성균관대학교 대학원 의학과 석사
1999.02 이화여자대학교 의과대학 졸업
약력/경력
2020.04 ~현재 삼성서울병원 혈액종양내과 교수
2019.04 ~ 현재 삼성서울병원 정밀의학연구소 혁신치료 센터장
2014.03 ~ 2020.03 삼성서울병원 혈액종양내과 부교수
2010.03 ~ 2014.02 삼성서울병원 혈액종양내과 조교수
2006.03 ~ 2010.02 삼성서울병원 혈액종양내과 임상조교수
학술지 논문
(2023)
Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer.
BIOMEDICINES.
11,
12
(2023)
Prevalence of RAF1 Aberrations in Metastatic Cancer Patients: Real-World Data.
BIOMEDICINES.
11,
12
(2023)
Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer.
SCIENCE ADVANCES.
9,
47
(2023)
The Clinical Implication of Conversion Surgery in Patients with Stage IV Gastric Cancer Who Received Systemic Chemotherapy.
BIOMEDICINES.
11,
11
(2023)
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer.
Oncology Research.
31,
6
(2023)
Impact of programmed death-ligand 1 (PD-L1) positivity on clinical and molecular features of patients with metastatic gastric cancer.
CANCER MEDICINE.
12,
18
(2023)
Tumor mutation burden in gastro-entero-pancreatic- neuroendocrine neoplasms.
JOURNAL OF GASTROINTESTINAL ONCOLOGY.
14,
4
(2023)
A Machine Learning Approach Using FDG PET-Based Radiomics for Prediction of Tumor Mutational Burden and Prognosis in Stage IV Colorectal Cancer.
CANCERS.
15,
15
(2023)
PIK3CA mutation subtype delineates distinct immune profiles in gastric carcinoma.
JOURNAL OF PATHOLOGY.
260,
4
(2023)
Clinical Implication of HER2 Aberration in Patients With Metastatic Cancer Using Next-Generation Sequencing: A Pan-Tumor Analysis.
JCO PRECISION ONCOLOGY.
7,
1
(2023)
The Optimal Tumor Mutational Burden Cutoff Value as a Novel Marker for Predicting the Efficacy of Programmed Cell Death-1 Checkpoint Inhibitors in Advanced Gastric Cancer.
JOURNAL OF GASTRIC CANCER.
23,
3
(2023)
TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
CANCER MEDICINE.
12,
11
(2023)
Xerna (TM) TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.
FRONTIERS IN ONCOLOGY.
13,
(2022)
MET gene alterations predict poor survival following chemotherapy in patients with advanced cancer.
PATHOLOGY & ONCOLOGY RESEARCH.
28,
-
(2022)
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
JOURNAL FOR IMMUNOTHERAPY OF CANCER.
-,
-
(2022)
Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer.
CANCER DISCOVERY.
12,
4
(2022)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
CLINICAL CANCER RESEARCH.
28,
7
(2022)
Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing.
JOURNAL OF ONCOLOGY.
2022,
-
(2022)
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy.
ANNALS OF ONCOLOGY.
33,
2
특허/프로그램
인공신경망을 이용한 위암의 예후 예측 방법, 장치 및 프로그램.
10-2019-7003924.
20201207.
대한민국
위암의 예후 예측용 PD-L1 마커 및 이의 용도.
10-2017-0182665.
20201202.
대한민국
항암 보조치료법의 선택을 위한 혈액 마커 및 이를 이용한 치료법 선택의 방법.
10-2018-0041926.
20200709.
대한민국
위암의 항암제 치료 반응성 예측용 바이오마커 및 이의 용도.
10-2018-0005488.
20200331.
대한민국
위암의 항암제 내성 진단용 바이오마커 및 이의 용도.
10-2017-0143200.
20200131.
대한민국
MCT의 발현 억제제 또는 활성 억제제를 유효성분으로 포함하는 암의 치료 또는 전이 억제용 조성물.
10-2018-0161963.
20200130.
대한민국
암의 복막 전이 진단을 위한 MCT4의 용도 (Uses of MCT4 for Diagnosing Peritoneal Metastasis).
10-2016-0085613.
20191122.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TIRAP 마커 및 이의 용도.
10-2017-0126732.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TLR3 마커 및 이의 용도.
10-2017-0126749.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 TLR7 마커 및 이의 용도.
10-2017-0126743.
20190826.
대한민국
소화기암 환자의 면역치료 반응성 예측용 CISH 마커 및 이의 용도.
10-2017-0126728.
20190823.
대한민국
위암의 예후 예측용 마커 및 이의 용도.
10-2017-0126718.
20190823.
대한민국
MET 저해제에 대한 감수성 예측용 조성물.
10-2016-0103773.
20190530.
대한민국
항암제 저항성 또는 민감성 예측용 조성물.
10-2016-0120762.
20190503.
대한민국
위암 아형의 분류 방법(Methods for classifying subunits of gastric cancer).
10-2016-0048347.
20181204.
대한민국
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
폴란드
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
스페인
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법 (MARKER FOR PREDICTING STOMACH CANCER PROGNOSIS AND METHOD FOR PREDICTING STOMACH CANCER PROGNOSIS).
11849123.2.
20180808.
독일
위암 진단방법 및 이를 이용한 위암 진단 키트.
10-2015-0082538.
20170926.
대한민국
위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
{Marker for Predicting Gastric Cancer Prognosis and Method for Predicting Gastric Cancer Prognosis Using the Same}.
13/994,072.
20160419.
미국
수상/공훈
2020 SKKU Excellence in Research Award
2019 (성균관대학교 의과대학 최우수 연구업적상)
2019 보건복지부 우수연구성과 공로상
2018 삼성서울병원 특별 의료 지표 공로상
2016 삼성서울병원 개원공로상
2016 삼성서울병원 최우수 연구업적상
2015 성균관대학교 최우수 연구업적상
학술회의논문
(2017)
NGS-guided Clinical Trials in Gastric Cancer.
2017 KCSG Annual Meeting.
대한민국
(2016)
Overview for Precision Medicine.
대한종양외과학회.
대한민국
(2016)
Clinical application of NGS in cancer.
기초의학학술대회.
대한민국
(2016)
Molecular targeted therapy for HCC: Learning from genome-matched trials in other solid cancer.
대한간암학회.
대한민국
(2016)
FPA144, a humanized monoclonal antibody for both FGFR2-amplified and nonamplified, FGFR2b-overexpressing gastric cancer patients..
American Society of Clinical Oncology.
미국
(2016)
Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy..
American Society of Clinical Oncology.
미국
(2016)
The NEXT-1 Trial at SMC: Is clinical sequencing beneficial to metastatic cancer patients?.
생화학분자생물학회지.
대한민국
(2016)
Clinical sequencing program in metastatic gastric cancer patients at SMC: translation from sequence - preclinical - clinical trials.
AACR.
미국
(2010)
A Phase II Trial of Neoadjuvant Erlotinib (TARCEVA) Followed by Surgery for Selected Patients with Stage IIIA, N2-Positive Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Thoracic Oncology.
대한민국
(2010)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor.
Journal of Thoracic Oncology.
대한민국
(2010)
Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Journal of Clinical Oncology.
미국
(2010)
Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients..
Journal of Clinical Oncology.
미국
(2010)
Molecular profiling of pulmonary plemorphic carcinoma: Implications for targeted treatment of a rare lung malignancy..
Journal of Clinical Oncology.
미국
(2010)
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Journal of Clinical Oncology.
미국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Clinical Oncology.
미국
(2010)
Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhbitor..
Journal of Clinical Oncology.
미국
(2010)
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy..
Journal of Clinical Oncology.
미국
발전기금
